Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries with Type 2 Diabetes Mellitus

Le résumé fourni par la source

Objective: Identifying social and economic factors associated with initiation of semaglutide or tirzepatide may inform strategies to support equitable uptake. Research Design and Methods: Cross-sectional study of 100% Medicare claims of patients ≥65 years with type 2 diabetes (T2DM). The outcome was initiation of semaglutide or tirzepatide. We calculated adjusted odds ratios (aOR) for each exposure (self-reported race/ethnicity, dual enrollment in Medicare and Medicaid, rurality, and social vulnerability index), accounting for demographic and clinical characteristics. Results: Among 13,922,387 patients with T2DM, 673,776 (4.8%) initiated semaglutide or tirzepatide in 2023. Minoritized racial/ethnic identity (e.g., non-Hispanic Black compared with White, aOR 0.72; 95% CI, 0.71–0.72), dual enrollment (aOR 0.90; 0.89–0.91), and residence in the most vs. least vulnerable socially vulnerable neighborhoods (aOR 0.93; 0.92–0.93) were associated with lower initiation. Conclusion: Minoritized racial/ethnic identity and adverse socioeconomic factors were associated with lower odds of initiation among Medicare beneficiaries with T2DM.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.